JNJ 74856665
Alternative Names: JNJ-6665; JNJ-74856665Latest Information Update: 28 Dec 2023
At a glance
- Originator Janssen Research & Development
- Class Antineoplastics
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in France (PO)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in South Korea (PO)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in Spain (PO)